Suppliers / Productos Farmaceuticos, S.A. de C.V

Productos Farmaceuticos, S.A. de C.V

Mexico Updated 9 July 2026

Productos Farmaceuticos, S.A. de C.V is a finished-dose manufacturer based in Mexico. It appears in 332 regulatory filings across 10 regulators, without an active US DMF or CEP on file. Its filings concentrate with INHRR (VE), ARCSA (EC) and DIGEMAPS (DO). Its GMP standing is certified by COFEPRIS (MX), INVIMA (CO) and US FDA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 19 May 2023 as NAI. Customs aggregates show $268K of exports covering 25 molecules to 1 destination in 2024.

0
active US DMFs
0
valid CEPs
6
registered plants 1 with an FDA FEI number
332
filings across 10 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 19 May 2023 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Condeixa-a-Nova, United Arab Emirates Not on file
Guarulhos (Estado De Sao Paulo), Colombia Not on file
Mexico, Mexico 3012456220
Miguel Hidalgo, Mexico Not on file
Rincón de Romos, Mexico Not on file
SAN MARTIN DE PORRES, Peru Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
INHRR (VE) 142 None
ARCSA (EC) 57 1
DIGEMAPS (DO) 51 None
MINSA (CR) 40 None
ANMAT (AR) 27 None
AEMPS (ES) 8 None
COFEPRIS (MX) None 2
INVIMA (CO) None 1
US FDA None 1

Scale

Year Revenue Exports Destinations
2024 Not reported $268K 1
2023 Not reported $3.6M 12
2022 Not reported $9.4M 14

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Productos Farmaceuticos, S.A. de C.V comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 19 May 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts